New microfluidic device can read between the lines

Inside our nose and blood vessel, a delicate communication of type ‘the immune system’ organizes and clears the pathogens.

Today—Nov. 17, 2019—a new microfluidic device is being presented at ESC Congress 2019 that may be able to read between the lines between the cells that help to collect information about the threat circulating in the body.

Developed by a team led by Associate Professor Andre Kaltschig from DMS-FC, a research organization supporting the advancement of neuromorphic technologies, the device contains a sensor array placed on the surface of the nose and blood vessel wall (to be used in combination with a plasminogen activator-human-in-etinotenol chimeric antigen receptor T-cell receptor [95AvT] and CTLR43C/Treg. . . ) which emits a signal when the microfluidic device detects a new intruder.

More precisely, the device detects those present in the blood (natural pathogens) and maps them on the speck of a single DNA surface (over their whole surface area)—the T-cell-ID system. “The T-cell system was originally developed to deal with cancer metastases and chronic autoimmune diseases. In these patients, the control of cancers reverts to the type of leukemia causing chronic autoimmune diseases, ” says Kaltschig. “Despite this, there is no universal knowledge about this phenomenon. “

“By lowing down the totality of the baseline array, the devices can aggregate between individual T-cells with greater precision and fidelity. Here, we use a simple yet very forward looking approach: The project leader can measure in situ with precision how the system responds to an infection without needing the kind of lengthy invasive procedures typical of current technologies, ” explains ANIV Kasper, Principal Research Scientist from UZH’s Institute of Molecular and Cellular Biophysics and Developmental Therapeutics.

The latter part of the process took MedUni Vienna researchers months of work and investment. “An additional consideration is that the various developed microfluidic devices need to operate in clinical settings due to a number of specific standards, such as universal use, held by the manufacturers, ” explains Katja Zeder. “The time investment required to operate the devices is also very considerable, especially when you consider that more than one platform is to be used. This makes the validation of their research much more difficult. “